AlloFuse

AlloSource Announces Two Presentations at the North American Spine Society Annual Meeting

Centennial, Colo. — September 25, 2018 — AlloSource, an organization dedicated to advancing the science and use of transplantable allogeneic cells and tissue, today announced two presentations on the use of biologics in spinal fusion surgery at AlloSource’s booth #2031 at the North American Spine Society (NASS) Annual Meeting on Thursday, September 27. Dr. Wellington K. Hsu will present on Novel Allograft Processing Methods to Improve Osteoinductivity and Clinical Outcomes at 12:10 p.m. Dr. Hsu is a Professor of Orthopaedic Surgery and Neurological Surgery at Northwestern University Feinberg School of Medicine in Chicago, Illinois and specializes in degenerative spine surgery, cervical spine surgery,…

AlloSource To Highlight AlloFuse Select CM Cellular AlloGraft Matrix At North American Spine Society Annual Meeting

Centennial, Colo. — October 24, 2017 — AlloSource, one of the nation’s largest providers of cellular, cartilage, bone, skin and soft-tissue allografts to advance patient healing in surgical procedures, will highlight AlloFuse® Select CM at the North American Spine Society Annual Meeting (NASS). AlloFuse Select CM combines osteoconductive, osteoinductive, and osteogenic properties to support the initiation and nurturing of bone growth, leading to consistent spinal fusion outcomes and delivering the benefits of autograft bone without the potential drawbacks. The product engages the body’s natural healing power and can be used in a variety of spinal, neurologic, and orthopedic procedures. “AlloFuse…

AlloSource Releases AlloFuse Line Extentsion

Company adds AlloFuse Select CM, a cellular allograft matrix, to the AlloFuse portfolio Centennial, Colo. — August 1, 2017 — AlloSource, one of the nation’s largest providers of cartilage, bone, skin, soft-tissue, and cellular allografts to advance patient healing in surgical procedures and wound care, today announced the release of AlloFuse® Select CM, a premium addition to AlloSource’s AlloFuse portfolio. AlloFuse Select CM combines osteoconductive, osteoinductive, and osteogenic properties to initiate and nurture bone growth, delivering the benefits of autograft bone without the potential drawbacks. The product is clinically proven to activate and support bone formation and can be used…

Theracell And AlloSource Announce Second Patent For Bone Fiber Technology

Demineralized Bone Fiber (DBF™) patent to expand TheraCell’s osteobiologic patent portfolio Northridge, Cali. and Centennial, Colo. — March 9, 2017 — TheraCell, a regenerative medicine company, today announced it was awarded a second patent for its demineralized bone fiber (DBF™) technology by the United States Patent and Trademark Office. The addition of U.S. Patent Number 9,572,912, titled Demineralized bone fibers having controlled geometry and shapes and methods thereof, expands TheraCell’s intellectual property portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry. TheraCell’s DBF™ technology is incorporated into two innovative demineralized cortical fiber allografts, AlloFuse® Cortical…

TheraCell And AlloSource Announce Issuance Of Patent For Bone Fiber Technology

Northridge, Calif. and Centennial, Colo. — Oct. 25, 2016 — TheraCell, a regenerative medicine company, today announced that the United States Patent and Trademark Office (USPTO) will issue TheraCell a patent for its demineralized bone fiber (DBF™) technology. The addition of this patent expands TheraCell’s patent portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry. TheraCell’s DBF technology is incorporated into two new innovative demineralized cortical fiber allografts, AlloFuse® Cortical Fibers and AlloFuse® Fiber Boats, provided by AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts. AlloFuse Cortical Fibers…